Cargando…

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer

Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foekens, J A, Diamandis, E P, Yu, H, Look, M P, Gelder, M E Meijer-van, Klijn, J G M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362687/ https://www.ncbi.nlm.nih.gov/pubmed/10070886 http://dx.doi.org/10.1038/sj.bjc.6690142

Ejemplares similares

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
por: Foekens, J A, et al.
Publicado: (1999)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
por: Luo, L-Y, et al.
Publicado: (2002)

Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease
por: Foekens, J A, et al.
Publicado: (2003)

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
por: Schuyer, M, et al.
Publicado: (2001)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010)

Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
por: Yu, H, et al.
Publicado: (1999)

The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines
por: Majumdar, S, et al.
Publicado: (1999)

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
por: Berns, E. M., et al.
Publicado: (1998)

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
por: Umar, Arzu, et al.
Publicado: (2009)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
por: Berns, E M J J, et al.
Publicado: (2001)

Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer
por: Sidiropoulos, M, et al.
Publicado: (2001)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
por: Schrohl, Anne-Sofie, et al.
Publicado: (2009)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer
por: Klijn, JGM, et al.
Publicado: (2005)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Utility of Free/Total Prostate Specific Antigen (f/t PSA) Ratio in Diagnosis of Prostate Carcinoma
por: Thakur, V., et al.
Publicado: (2004)

Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
por: Sieuwerts, Anieta M., et al.
Publicado: (2014)

Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility
por: Gupta, Nishi, et al.
Publicado: (2017)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy
por: Hara, N, et al.
Publicado: (2001)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Survey of the rate of PSA testing in general practice
por: Melia, J, et al.
Publicado: (2001)

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer
por: Kim, H, et al.
Publicado: (2001)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2022)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_d7no0bmlf45uslhn2ub5vdgmdj